High-glucose, AGE, angiotensin II, and pro-inflammatory cytokines, such as TWEAK and parathyroid hormone-related protein (PTHrP) AGE promote EGFR transactivation in kidney cells [92–96]In this regard, TWEAK targeting antibodies are undergoing clinical trials in kidney disease, while targeting the TWEAK receptor Fn14 reduced colon cancer metastasis in experimental animals [95, 97]. Here, TNFRSF12A is linked to kidney disorder.